BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focused on developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced that management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, held on September 14-16, 2026 in New York City, NY. The presentation underscores the company's commitment to addressing the critical need for new treatments against resistant bacterial infections.
BioVersys's Chief Financial Officer, Hernan Levett, will deliver a live presentation on September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room on the 4th floor of the Lotte New York Palace. Additionally, Dr. Marc Gitzinger, Chief Executive Officer, will provide an on-demand presentation starting September 11, 2026, at 7:00 AM ET, with a replay available for 90 days. The webcast can be accessed through the H.C. Wainwright platform or via the BioVersys website in the investor section.
This participation is significant as it provides an opportunity for BioVersys to showcase its pipeline and strategic direction to the investment community. The company is at a pivotal stage, with its lead program BV100 for Acinetobacter baumannii infections in Phase 3, and alpibectir for tuberculosis in Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium from the University of Lille, France. These programs target some of the most challenging multidrug-resistant pathogens, which the World Health Organization has identified as critical priorities for new antibiotics.
BioVersys leverages two proprietary technology platforms, TRIC and Ansamycin Chemistry, to develop candidates that overcome resistance mechanisms, block virulence production, and directly affect bacterial pathogenesis. This approach aims to address high unmet medical needs in antimicrobial and microbiome fields, offering potential new treatment options for life-threatening infections and bacteria-exacerbated chronic inflammatory disorders.
The conference presentation will likely highlight recent progress and future milestones, offering investors insight into the company's growth potential. With the global rise of antimicrobial resistance, BioVersys's work is more crucial than ever. The company's presence at the H.C. Wainwright conference underscores its active engagement with the financial community to support the development of its promising pipeline.
